Skip Navigation


Brain Advance Access originally published online on February 25, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
127/5/1085    most recent
awh127v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhang, G.
Right arrow Articles by Sheikh, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, G.
Right arrow Articles by Sheikh, K. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 127, No. 5, 1085-1100, 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh127

Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies

G. Zhang1,3, P. H. H. Lopez1, C. Y. Li3, N. R. Mehta2, J. W. Griffin1, R. L. Schnaar2 and K. A. Sheikh1

Departments of 1 Neurology and 2 Pharmacology, Johns Hopkins University, Baltimore, MD, USA and 3 Department of Neurology, The Second Teaching Hospital, Hebei Medical University, Shijiazhuang, People’s Republic of China

Correspondence to: Dr Kazim Sheikh, Department of Neurology, Johns Hopkins Hospital, 600 N. Wolfe St, 509 Pathology Building, Baltimore, MD 21287, USA E-mail: ksheik{at}jhmi.edu

Antibodies against GD1a, GM1 and related gangliosides are frequently present in patients with the motor variant of Guillain–Barré syndrome (GBS), and their pathological role in this variant of GBS is now widely accepted. However, two basic issues related to anti-ganglioside antibody-mediated neural injury are not completely resolved: (i) some anti-ganglioside antibodies can cross-react with glycoproteins and therefore the nature of antigens targeted by these antibodies is not well established; and (ii) although pathological studies suggest that complement activation occurs in GBS, experimental data for the role of complement remain inconclusive. To address these issues, we developed and characterized a simple anti-ganglioside antibody-mediated cytotoxicity assay. Our results demonstrate first, that both GBS sera containing anti-ganglioside antibodies and monoclonal anti-ganglioside antibodies cause neuronal cell lysis by targeting specific cell surface gangliosides, and secondly, that this cell lysis is complement dependent. In this assay, the GD1a cell membrane pool appears to be more susceptible to anti-ganglioside antibody-mediated injury than the GM1 pool. Further, human intravenous immunoglobulin (IVIg), now a standard treatment for GBS, significantly decreased cytotoxicity in this assay. Our data indicate that the mechanisms of IVIg-mediated protection in this assay include anti-idiotypic antibodies and downregulation of complement activation. This simple cytotoxicity assay can potentially be used for screening of (i) pathogenic anti-ganglioside antibodies in patients with immune-mediated neuropathies; and (ii) new/experimental therapies to prevent anti-ganglioside antibody-mediated neural injury.

Key Words: cytotoxicity assay; Guillain–Barré syndrome; acute motor axonal neuropathy; anti-ganglioside antibodies; IVIg

Abbreviations: Ab= antibody; AMAN = acute motor axonal neuropathy; ELISA = enzyme-linked immunosorbent assay; GBS = Guillain–Barré syndrome; IgG = immunoglobulin G; IgM = immunoglobulin M; IVIg = human intravenous immunoglobulin; LDH = lactate dehydrogenase; mAb = monoclonal antibody; P4 = 1-phenyl-2-hexade-canolamino-3-morpholino-1-propanol; TLC = thin-layer chromatography

Received October 8, 2003. Revised December 18, 2003. Accepted December 22, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
P. H. H. Lopez, G. Zhang, M. A. Bianchet, R. L. Schnaar, and K. A. Sheikh
Structural requirements of anti-GD1a antibodies determine their target specificity
Brain, July 1, 2008; 131(7): 1926 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
H. C. Lehmann and H.-P. Hartung
Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies
Brain, May 1, 2008; 131(5): 1168 - 1170.
[Full Text] [PDF]

Home page
 J. Neurosci.Home page
H. C. Lehmann, P. H. H. Lopez, G. Zhang, T. Ngyuen, J. Zhang, B. C. Kieseier, S. Mori, and K. A. Sheikh
Passive Immunization with Anti-Ganglioside Antibodies Directly Inhibits Axon Regeneration in an Animal Model
J. Neurosci., January 3, 2007; 27(1): 27 - 34.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Geleijns, A. Roos, J. J. Houwing-Duistermaat, W. van Rijs, A. P. Tio-Gillen, J. D. Laman, P. A. van Doorn, and B. C. Jacobs
Mannose-Binding Lectin Contributes to the Severity of Guillain-Barre Syndrome
J. Immunol., September 15, 2006; 177(6): 4211 - 4217.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. A. Goodfellow, T. Bowes, K. Sheikh, M. Odaka, S. K. Halstead, P. D. Humphreys, E. R. Wagner, N. Yuki, K. Furukawa, K. Furukawa, et al.
Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy
J. Neurosci., February 16, 2005; 25(7): 1620 - 1628.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.